Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

OBJECTIVE - A double-blind placebo controlled study investigated long-term effects oi Ergoset, anew quick release formulation of bromocriptine, on body weight, body fat, and glucose tolerance in a group (n = 17) of obese subjects who were instructed to follow a moderate hypocaloric diet. RESEARCH DESIGN AND METHODS - Obese individuals (>25% body fat for men and >30% body fat for women) were instructed to follow a calorie-restricted diet (70% of weight maintaining based on study entry weight) and were randomized to daily treatment with Ergoset (1.6-2.4 mg/day) or placebo at 0800 over an 18-week treatment period. Oral glucose tolerance tests were performed on subjects before initiation and again at termination oi treatment. Body weight and body fat (determined by skinfold measurements) were quantified every 2 weeks during the course oi treatment. RESULTS - Ergoset treatment for 18 weeks significantly reduced body weight and body far versus placebo (6.3 +/- 1.5 and 5.4 +/- 1.1 kg vs. 0.9 +/- 1.0 and 1.5 +/- 0.6 kg, respectively, P < 0.01). Ergoset, but not placebo, also improved glucose tolerance (P < 0.02); the stimulated area under the oral glucose tolerance curve was reduced by 46% (from 121 +/- 23 to 64 +/- 32 mg . h(-1). dl(-1)), while the stimulated area under the insulin curve was reduced by 30%. CONCLUSIONS - When combined with instruction to follow a moderate hypocaloric diet, Ergoset, but not placebo, improves glucose tolerance and promotes significant weight and body fat loss in obese subjects over an 18-week treatment period.